Patients with oropharyngeal cancers who were treated with proton therapy, compared to traditional radiation therapy saw a significant survival benefit, according to the findings from a phase III trial led by researchers at the University of Texas MD Anderson Cancer Center.Â
A guideline from the American Society of Clinical Oncology offers clear, evidence-based direction for treating blood cancers during pregnancy and shows that many patients can safely receive timely cancer care without compromising fetal health.Â
American Cancer Society scientists report higher cancer mortality rates among adults living in rural areas, certain congressional districts, and among those with lower socioeconomic status, according to a report published this month.Â
A study led by The Ohio State University Comprehensive Cancer Center—Arthur G. James Cancer Hospital and Richard J. Solove Research Institute found the drug pirtobrutinib worked as well as another drug, ibrutinib, in the treatment of chronic lymphocytic leukemia and small lymphocytic lymphoma, and people in the study responded better with pirtobrutinib.
Researchers presented updated data at ESMO IO from the phase III POD1UM-303/InterAACT 2 trial of retifanlimab-dlwr (Zynyz) in combination with platinum-based chemotherapy (carboplatin and paclitaxel) in adult patients with squamous cell carcinoma of the anal canal.Â
Cedars-Sinai investigators, leading a multi-institutional team, have developed and validated a tool to predict which patients with pancreatic neuroendocrine tumors need closer monitoring because their cancer is more likely to recur.
With vague symptoms and no screening test, ovarian cancer can be deadly. According to NCI’s Surveillance, Epidemiology and End Results program, 20,890 people will receive an ovarian cancer diagnosis in 2025 and of these, more than half will learn that their ovarian cancer has spread to distant organs.
Personalis Inc. announced the publication of one of the largest and most comprehensive patient cohorts to date from the landmark TRACERx study, which demonstrated the clinical importance of ultrasensitive, tumor-informed molecular residual disease testing in stage 1 to 3 non-small cell lung cancer.
Researchers have presented the initial findings from a major multi-year collaboration between the ECOG-ACRIN Cancer Research Group and Caris Life Sciences focused on transforming recurrence risk assessment in early-stage breast cancer through artificial intelligence.
The American Cancer Society is introducing two key changes for cervical cancer screening guidelines.Â
